Merck’s $3B return to eye disease; J&J’s $1.25B tuck-in; Keytruda challenger steals #ASCO24 show; and more

Women who received false-positive mammography results were less likely to return for screening, especially if they received recommendations for short-interval follow-up or biopsy, according to

British drug­mak­er GSK plans to ac­quire an ex­per­i­men­tal he­pati­tis B drug from John­son & John­son and its de­vel­op­er Ar­row­head Phar­ma­ceu­ti­cals and then com­bine the siR­NA